A Multicenter, Double Blind, Placebo Controlled Randomized Study of the Efficacy and Safety of Two Rimonabant/Metformin Combinations for Reducing A1C in the Treatment of Patients With Type 2 Diabetes Mellitus Who Are Not on Current Drug Therapy.

Next Previous
Trial Profile

A Multicenter, Double Blind, Placebo Controlled Randomized Study of the Efficacy and Safety of Two Rimonabant/Metformin Combinations for Reducing A1C in the Treatment of Patients With Type 2 Diabetes Mellitus Who Are Not on Current Drug Therapy.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Rimonabant (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 This trial has been completed in Slovakia as per European Clinical Trials Database record.
    • 13 May 2016 Status changed from discontinued to withdrawn prior to enrolment due to company decision taken in light of demands by certain national health authorities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top